New hope for hard-to-treat cancers: experimental drug targets HER2-positive tumors
NCT ID NCT07309770
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests a drug called trastuzumab rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. About 90 participants with three types of cancer (extramammary Paget's disease, rare solid tumors, or urothelial carcinoma) will receive the drug every three weeks. The goal is to see if the drug can shrink tumors and how long it keeps the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-DRUG CONJUGATES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.